Finch Therapeutics cuts 37% workforce, suspends FIN-211 trial after Takeda deal ends

Finch Therapeutics Group, Inc.

Reduces workforce by 50 employees (~37% of staff) to cut costs.
Suspends initiation of Phase 1 trial for FIN-211 (autism candidate).
Estimates $1.6M in severance and related expenses; charges expected in H2 2022.
Action follows termination of Takeda IBD collaboration and ongoing strategic review.
Restructuring substantially complete by Q4 2022; cash runway update to come.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.